ChemotherapyFDA-approvedFirst-line
Leucovorin
How it works
Inhibits the enzyme dihydrofolate reductase (DHFR), which is involved in DNA synthesis, and can help reduce the toxicity of 5-FU.
Cancer types
Efficacy
In clinical trials, leucovorin improved overall survival and progression-free survival in patients with metastatic colorectal cancer, with a median survival of approximately 12.6 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Leucovorin Improves Survival in Metastatic Colorectal Cancer | Colorectal Cancer | observational | Mortality occurred in 38.8% of patients receiving fluorouracil with leucovorin compared with 47.1% receiving fluorouracil alone (hazard ratio 0.752, 95% CI 0.690-0.821). | Source → |
| Rare Allergic Reaction to Common Cancer Treatment Identified | Colorectal Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.